Last update 02 Aug 2025

JNJ-86974680

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
JNJ 86974680, JNJ86974680
Target
A2aR
Action
antagonists
Mechanism
A2aR antagonists(Adenosine A2a receptor antagonists)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication
Advanced Lung Non-Small Cell Carcinoma
Inactive Indication-
Originator Organization
Johnson & JohnsonJohnson & Johnson
Active Organization
Johnson & JohnsonJohnson & Johnson
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with JNJ-86974680
NCT06116786
/ RecruitingPhase 1
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer
100 Clinical Results associated with JNJ-86974680
Login to view more data
100 Translational Medicine associated with JNJ-86974680
Login to view more data
100 Patents (Medical) associated with JNJ-86974680
Login to view more data
100 Deals associated with JNJ-86974680
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 1
United States
Johnson & JohnsonJohnson & Johnson
27 Nov 2023
Advanced Lung Non-Small Cell CarcinomaPhase 1
Germany
Johnson & JohnsonJohnson & Johnson
27 Nov 2023
Advanced Lung Non-Small Cell CarcinomaPhase 1
South Korea
Johnson & JohnsonJohnson & Johnson
27 Nov 2023
Advanced Lung Non-Small Cell CarcinomaPhase 1
Spain
Johnson & JohnsonJohnson & Johnson
27 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free